Click here to learn more

GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years and as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).

Diagnosing and Treating Multifocal Motor Neuropathy (MMN)

What is MMN?

MMN is a rare immune-mediated motor neuropathy, which presents as slowly progressive, asymmetric, and predominantly distal limb weakness.1,2

Weakness typically begins in the fingers or thumb and may include involuntary fasciculations and cramping. As the disease advances, patients may experience wrist drop, foot drop, and/or loss of grip strength, and weakness may move proximally.2-4

US map with the numbers 1-2. 1-2

MMN has a prevalence of
1-2 in 100,0002

Three male pins and one female pin icon.

MMN affects nearly 3x
more men than women1

Scale of numbers between 20 and 70 with icon pointing at the number 40. years 30 40 50 60 70 20

Mean age onset of 40 years
(range 20-70 years)1

Diagnosis is often delayed

MMN presents with symptoms similar to those of other neuropathies, such as amyotrophic lateral sclerosis (ALS). As a result, misdiagnosis does occur and contributes to delays in diagnosis.1

Unfortunately, for many patients it can take a considerable amount of time from symptom onset to receiving a diagnosis. The mean time to diagnosis is 6 years (range: <1-23 years).4* If left undiagnosed and unmanaged, MMN continues to progress.1,3

Undiagnosed and unmanaged, MMN continues to progress1,3

Hurting hand and checklist icon. 6 years is the mean time of MMN diagnosis. 6 years * (range: <1-23 years) *Mean time it takes to get MMN diagnosed based on a retrospective case cohort study of 47 patients with MMN followed for up to 12 years. Symptom onset Diagnosis 4
Diagnosis 4 6 years * (range: <1-23 years) Symptom onset *Mean time it takes to get MMN diagnosed based on a retrospective case cohort study of 47 patients with MMN followed for up to 12 years.

AMEND the time to diagnosis

When considering MMN, AMEND—an acronym created by TAKEDA—can help you recognize some of the hallmark symptoms.

  • Letter A for Asymmetric. Asymmetric
    Distribution of weakness is asymmetric2-4
  • Letter M for Motor. Motor without sensory
    Motor impairment (muscle weakness) without objective sensory impairment3
  • Letter E for Elevated. Elevated anti-GM1 antibody titers
    Present in around 50% of patients5
  • Letter N for Nerve. Nerve conduction block
    Typically present, but may be activity dependent and difficult to detect. May be easier to detect in advanced disease1,2,6
  • Letter D for Distal. Distal
    Most common clinical presentation of weakness typically affects the distal arm/leg muscles2-4

In addition to the above, muscle mass is preserved despite profound weakness in early disease but may be decreased due to atrophy in advanced disease. Axonal damage and loss are correlated with muscle weakness and may be less pronounced in early stages.

It is important to diagnose MMN as early as possible

Though MMN cannot be cured, many patients respond to treatment. Disease progression depends on how long patients remain undiagnosed.1,2

Woman brushing her hair in the mirror.
Stethoscope icon.

GAMMAGARD LIQUID is the first and only FDA-approved treatment for adults with MMN8

Review clinical trial
Safety icon.

Review the safety profile established in the largest controlled clinical trial for MMN to date8,9

See safety profile